| Factor Information | |
|---|---|
| Data ID | 3636 |
| Factor | Duration of supplemental O2 |
| Description | N/A |
| Biomarker | NA |
| Classification | A12 (clinical factor - treatment) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | To obtain population based RSV hospitalisation rates in children ,24 months of age with CHD. |
| p Value | 0.023 |
| Conclusion | RSV hospitalisation rates in CHD patients were fourfold lower than reported from the USA. Based on these low rates and RR, unrestricted use of palivizumab does not appear to be justified in this study area. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 148 |
| CHD Type | NA |
| CHD Subtype | NA |
| Reference | |
|---|---|
| PMID | 15383442 |
| Year | 2015 |
| Title | Low incidence of respiratory syncytial virus hospitalisations in haemodynamically significant congenital heart disease. |
| Sample | ||
|---|---|---|
| Population | Children | |
| Source | patients | |
| Region | Bern, Switzerland | |
| Method | population based study | |
| Race | European | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | CHD patients(Treatment) | Non-CHD patients(Control) |
| Number | 10 | 719 |
| Age | 5.7 [2.1–19.4] months | 3.7 [0.2–23.6] months |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | 5(1-34) | 2(0-26) |
